Drug Listing Act of 1972: NDC Rules & Registration Requirements

---

This guide breaks down the core requirements of the 1972 Act, including establishment registration rules and the National Drug Code (NDC) system, for pharma professionals, pharmacy staff, healthcare providers, and even consumers seeking to understand how U.S. drug tracking works.#

Table of Contents#

1. Background & Core Purpose of the Drug Listing Act of 1972
2. Mandate 1: Drug Establishment Registration Rules
3. Mandate 2: National Drug Code (NDC) System Requirements
4. Key Amendments & Updates to the 1972 Act
5. Real-World Impacts for All Stakeholders
6. Common Compliance Pitfalls to Avoid
7. Final Takeaways
8. References

---

Background & Core Purpose of the Drug Listing Act of 1972#

Prior to 1972, the FDA had no centralized database of drug manufacturers or marketed drug products in the U.S. This lack of visibility led to:

• Widespread circulation of unlabeled or counterfeit drugs
• Slow, disorganized recall processes that put patients at risk
• Inconsistent adverse event reporting, with no way to tie safety issues to specific manufacturers or product versions
• Gaps in supply chain tracking for both prescription and over-the-counter (OTC) medications

The Drug Listing Act was enacted on October 27, 1972, with three explicit goals:

1. Create a mandatory registry for all facilities that produce drugs for U.S. distribution
2. Establish a standardized, unique identifier for every marketed drug product
3. Improve the FDA’s ability to monitor drug safety, respond to public health emergencies, and enforce manufacturing standards

---

Mandate 1: Drug Establishment Registration Rules#

The first core requirement of the 1972 Act is mandatory registration for all drug establishments operating in or supplying the U.S. market.

Who must register?#

All domestic and foreign facilities that manufacture, prepare, propagate, compound, repackage, relabel, or process prescription or OTC drugs intended for U.S. distribution, including:

• Active Pharmaceutical Ingredient (API) manufacturers
• Finished dosage form producers
• Repackagers and private label distributors
• 503B outsourcing facilities that produce bulk compounded drugs
• Facilities that produce drug samples for healthcare providers

Exemptions from registration#

A small set of facilities are not required to register, including:

• Retail pharmacies that compound drugs exclusively for individual patient prescriptions
• Licensed healthcare providers that compound drugs for use in their own practice
• Facilities that only produce drugs for non-clinical research use (not commercial distribution)

Registration process rules#

1. Initial registration: New facilities must submit registration to the FDA within 5 days of beginning operations, via the FDA’s electronic Drug Registration and Listing System (eDRLS)
2. Annual renewal: All registered facilities must renew their registration between October 1 and December 31 of every year
3. Updates: Facilities must submit updated registration information within 30 days of any material change, including changes to ownership, facility location, product lines, or primary contact details

Penalties for non-compliance#

Unregistered facilities face severe consequences, including:

• Classification of all their products as adulterated and misbranded under the FD&C Act
• Seizure of drug products by the FDA
• Civil monetary penalties of up to $1 million per violation under 21 U.S.C. § 333(f)
• Blocking of foreign drug shipments at U.S. ports of entry

---

Mandate 2: National Drug Code (NDC) System Requirements#

The second core mandate of the 1972 Act is the creation of the National Drug Code (NDC) system, a universal, unique identifier for all marketed drug products in the U.S.

NDC Format Rules#

All NDCs are 10-digit, 3-segment numbers, with variable segment lengths that add up to 10 total digits:

1. Labeler code (4-6 digits): Assigned directly by the FDA to the firm that markets the drug (the labeler, e.g. a pharmaceutical company or private label distributor)
2. Product code (3-4 digits): Assigned by the labeler, identifies the specific drug's active ingredients, strength, and dosage form
3. Package code (1-2 digits): Assigned by the labeler, identifies the package size and type (e.g. 100-tablet bottle vs. 30-tablet blister pack)

Note: Most pharmacy billing and insurance systems use an 11-digit NDC, which adds a leading zero to standardize segment lengths for automated processing. Only the 10-digit format is official for FDA listing purposes. Additionally, a final FDA rule published in March2026 will transition all NDCs to a uniform 12-digit, 6-4-2 format effective March7,2033.

NDC Assignment & Listing Rules#

1. Labelers must first request an FDA-assigned labeler code before assigning product and package codes
2. All NDCs must be listed with the FDA within 30 days of the product being first marketed in the U.S.
3. Labelers must update NDC listings within 30 days of any material change to the product (e.g. strength adjustment, new packaging, updated labeling)
4. Labelers must discontinue NDC listings within 30 days of stopping sales of the associated product
5. NDCs are required for all prescription drugs, OTC monograph drugs, and 503B compounded drug products. Exempt products include dietary supplements, cosmetics, medical devices, and custom-compounded drugs for individual patients.

---

Key Amendments & Updates to the 1972 Act#

The original 1972 legislation has been updated several times to address evolving drug safety needs:

1. 2003 Medicare Modernization Act: Required NDCs to be printed on all prescription drug labels to streamline insurance billing and reduce claim errors
2. 2012 FDASIA: Strengthened drug supply chain safety with new authorities for the FDA, including requirements for unique facility identifiers for drug establishment registration and provisions to address challenges in the global drug supply chain
3. 2020 CARES Act: Reformed the OTC drug monograph process by adding Section 505G to the FD&C Act, creating a streamlined administrative order process for OTC monograph drugs and establishing the OTC Monograph Drug User Fee Program (OMUFA) to fund FDA oversight
4. 2026 Final 12-Digit NDC Rule: On March 5, 2026, the FDA published a final rule updating the NDC format from a variable 10-digit code to a uniform 12-digit, 6-4-2 format. The rule takes effect on March 7, 2033, giving the industry a seven-year transition period. All existing 10-digit NDCs will be automatically converted to the new format by adding leading zeros to each segment. A three-year labeling transition period (through March 6, 2036) allows companies to update drug labels to reflect the new 12-digit NDC.

---

Real-World Impacts for All Stakeholders#

The Drug Listing Act of 1972 delivers tangible benefits across the U.S. healthcare ecosystem:

• For the FDA: Enables fast, targeted drug recalls (e.g. the 2022 pediatric acetaminophen shortage response relied on NDC data to track supply gaps and redirect stock), and improves adverse event reporting by tying safety reports to specific products and manufacturers
• For pharmacies and payers: Reduces billing errors, streamlines inventory management, and supports compliance with the Drug Supply Chain Security Act (DSCSA) requirements to verify product legitimacy
• For consumers: The public FDA NDC Directory allows patients to look up any drug’s manufacturer, strength, and dosage form, and check for active recalls associated with their medication.

---

Common Compliance Pitfalls to Avoid#

1. Late annual registration: Missing the December 31 renewal deadline can lead to deactivation of your labeler code, invalidating all existing NDCs associated with your firm
2. Outdated NDC listings: Failing to update or discontinue NDCs after product changes or discontinuation leads to supply chain confusion and insurance claim denials
3. Incorrect NDC formatting: Using the 11-digit billing NDC for FDA listing submissions will result in rejected listings
4. Forgotten foreign facility registration: Non-U.S. manufacturers that ship to the U.S. are required to register, even if they only sell to U.S. distributors, and unregistered facilities will have their shipments seized at the border

---

Final Takeaways#

The Drug Listing Act of 1972 is the foundation of U.S. drug safety and supply chain transparency. Its registration and NDC requirements are not just regulatory red tape: they reduce counterfeit drug risk, speed up public health emergency responses, and reduce administrative friction for pharmacies and payers. Stakeholders should prepare for the FDA’s final 12-digit NDC format, which takes effect on March 7, 2033, to ensure ongoing compliance as the system evolves.

---

References#

1. U.S. Food and Drug Administration. (2023). ANNEX B – The Drug Listing Act of 1972 Information Bulletin. Retrieved from https://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/annex-b-drug-listing-act-1972-information-bulletin
2. U.S. Food and Drug Administration. (2026). Revising the National Drug Code Format and Drug Label Barcode Requirements – Final Rule. Retrieved from https://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/national-drug-code-format
3. U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
4. 21 U.S.C. § 333 – Penalties. Retrieved from https://www.law.cornell.edu/uscode/text/21/333